Zacks Investment Research upgraded shares of Aileron Therapeutics (NASDAQ:ALRN) from a hold rating to a buy rating in a research report released on Tuesday morning. They currently have $1.25 price objective on the stock.
According to Zacks, “Aileron Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engages in developing and commercializing a novel class of therapeutics primarily in the United States. The companys lead product includes ALRN-6924, targets the tumor suppressor protein p53 for the treatment of a range of cancers which are in clinical stage. Aileron Therapeutics, Inc. is based in Cambridge, Massachusetts. “
Separately, ValuEngine raised Aileron Therapeutics from a hold rating to a buy rating in a research report on Thursday, November 1st.
Aileron Therapeutics stock opened at $1.14 on Tuesday. The company has a current ratio of 4.23, a quick ratio of 4.23 and a debt-to-equity ratio of 0.19. The company has a market cap of $16.81 million, a price-to-earnings ratio of -0.64 and a beta of 2.14. Aileron Therapeutics has a fifty-two week low of $0.52 and a fifty-two week high of $10.00.
Aileron Therapeutics (NASDAQ:ALRN) last posted its quarterly earnings data on Wednesday, November 7th. The company reported ($0.50) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.58) by $0.08. As a group, analysts forecast that Aileron Therapeutics will post -2.15 earnings per share for the current year.
A number of institutional investors have recently bought and sold shares of the business. Millennium Management LLC boosted its position in Aileron Therapeutics by 565.4% during the 2nd quarter. Millennium Management LLC now owns 123,658 shares of the company’s stock valued at $670,000 after acquiring an additional 105,073 shares in the last quarter. Bridgeway Capital Management Inc. boosted its position in Aileron Therapeutics by 78.6% during the 3rd quarter. Bridgeway Capital Management Inc. now owns 113,600 shares of the company’s stock valued at $312,000 after acquiring an additional 50,000 shares in the last quarter. Vanguard Group Inc boosted its position in shares of Aileron Therapeutics by 8.0% in the 3rd quarter. Vanguard Group Inc now owns 96,415 shares of the company’s stock worth $265,000 after purchasing an additional 7,109 shares in the last quarter. Parkwood LLC bought a new stake in shares of Aileron Therapeutics in the 3rd quarter worth approximately $149,000. Finally, Renaissance Technologies LLC bought a new stake in shares of Aileron Therapeutics in the 3rd quarter worth approximately $137,000. 12.72% of the stock is currently owned by institutional investors and hedge funds.
About Aileron Therapeutics
Aileron Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of therapeutics in the United States. The company's lead product candidate is ALRN-6924, a stapled peptide, which is in Phase I clinical trial for the treatment of advanced solid tumors or lymphomas; Phase IIa clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and Phase IIb trial to treat AML/MDS in combination with cytosine arabinoside.
Featured Article: Discover Your Risk Tolerance
Get a free copy of the Zacks research report on Aileron Therapeutics (ALRN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aileron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aileron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.